Arcturus Therapeutics(US:ARCT) ZACKSยท2025-11-04 05:02Core Viewpoint - Arcturus Therapeutics (ARCT) is anticipated to report a significant year-over-year decline in earnings and revenues for the quarter ended September 2025, which could influence its stock price depending on the actual results compared to estimates [1][3]. Financial Expectations - The company is expected to post a quarterly loss of $1.25 per share, reflecting a year-over-year change of -380.8% [3]. - Revenues are projected to be $11.39 million, down 72.7% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 4.21% lower in the last 30 days, indicating a bearish sentiment among analysts regarding the company's earnings prospects [4][12]. - The Most Accurate Estimate is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -4.59% [12]. Earnings Surprise Prediction - A positive Earnings ESP is generally a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [10]. - However, Arcturus Therapeutics currently holds a Zacks Rank of 4, making it challenging to predict an earnings beat [12]. Historical Performance - In the last reported quarter, the company was expected to post a loss of $1.11 per share but actually reported a loss of -$0.34, resulting in a surprise of +69.37% [13]. - Over the past four quarters, Arcturus has beaten consensus EPS estimates three times [14]. Industry Context - In the broader Zacks Medical - Biomedical and Genetics industry, Iovance Biotherapeutics (IOVA) is also expected to report a loss, with a consensus EPS estimate of -$0.29 per share, indicating a year-over-year change of -3.6% [18]. - Iovance's revenue is expected to be $70.34 million, up 20.1% from the previous year, but it also has a Zacks Rank of 4, complicating predictions for an earnings beat [19][20].